Ausgabe 4/2019
Inhalt (15 Artikel)
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
- Open Access
- B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Murali Kesavan, Toby A. Eyre, Graham P. Collins
Targeting Translation of mRNA as a Therapeutic Strategy in Cancer
- B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Ipsita Pal, Maryam Safari, Marko Jovanovic, Susan E. Bates, Changchun Deng
Considerations for the Treatment of Diffuse Large B Cell Lymphoma in the Elderly
- B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
Yasir Khan, Elizabeth A. Brem
Mantle Cell Lymphoma: Which Patients Should We Transplant?
- B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)
James N. Gerson, Stefan K. Barta
Pathogen-Specific T Cells Beyond CMV, EBV and Adenovirus
- CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Wei Jiang, Barbara Withers, Gaurav Sutrave, Leighton E. Clancy, Michelle I. Yong, Emily Blyth
Induced Pluripotent Stem Cell (iPSC)–Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges
- Open Access
- CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Alexandros Nianias, Maria Themeli
Overcoming Challenges in Process Development of Cellular Therapies
- CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Steven L. Highfill, David F. Stroncek
Towards Automated Manufacturing for Cell Therapies
- CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
David Smith, Thomas R. J. Heathman, Alex Klarer, Courtney LeBlon, Yasuhiko Tada, Brian Hampson
Tumor-Infiltrating Lymphocytes in the Checkpoint Inhibitor Era
- CART and Immunotherapy (M Ruella and P Hanley, Section Editors)
Gerald P. Linette, Beatriz M. Carreno
Exploring a Future for PI3K Inhibitors in Chronic Lymphocytic Leukemia
- Chronic Lymphocytic Leukemias (N Jain, Section Editor)
Krish Patel, John M. Pagel
Relevance of Prognostic Factors in the Era of Targeted Therapies in CLL
- Chronic Lymphocytic Leukemias (N Jain, Section Editor)
Adam S. Kittai, Matthew Lunning, Alexey V. Danilov
The Rationale for Immunotherapy in Myeloproliferative Neoplasms
- Myeloproliferative Neoplasms (B Stein, Section Editor)
Lucia Masarova, Prithviraj Bose, Srdan Verstovsek
Emerging Role of Integrative Medicine in Hematologic Malignancies: a Literature Review and Update on Current Trends in Complementary Medical Practices in Hematologic Cancers
- Health Economics (N Khera, Section Editor)
Onyemaechi N. Okolo, Krisstina Gowin
Is There a Role for Dose Modification of TKI Therapy in CML?
- Open Access
- Chronic Myeloid Leukemias (M Mauro, Section Editor)
M. Copland
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS
- Myelodysplastic Syndromes (M Savona, Section Editor)
Rami S. Komrokji
